Short answer
Harmony Biosciences Holdings, Inc. (HRMY) filed an 8-K current report with the SEC on April 14, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). CFO Sandip Kapadia departed April 14, 2026 to pursue other opportunities, triggering severance under existing employment and award agreements.
Harmony Biosciences Holdings, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- CFO Sandip Kapadia departed April 14, 2026 to pursue other opportunities, triggering severance under existing employment and award agreements
- Glenn Reicin appointed CFO effective April 14, 2026, bringing prior CFO experience at Eccogene, Alladapt Immunotherapeutics, and Sigilon Therapeutics
- Reicin receives $500,000 base salary and 50% target annual bonus opportunity
- $3,000,000 option award vests 25% after one year and 75% quarterly through the fourth anniversary
- Change-in-control protection includes pro-rata bonus and full option acceleration following qualifying termination
Item 7.01 · Regulation FD Disclosure
- Reg FD section contains only incorporation-by-reference language
- No substantive company disclosure or market-moving information provided
Item EX-99.1 · Exhibit EX-99.1
- Glenn Reicin appointed CFO effective immediately, adding capital-markets, fundraising, and financial-planning experience
- Sandip Kapadia departs CFO role after supporting Harmony’s financial profile and growth strategy
- 2026 net product revenue guidance reiterated at $1.0–$1.04 billion from WAKIX sales
- New CFO mandate includes capital allocation, treasury, investor relations, and risk management during expansion
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Harmony Biosciences Holdings, Inc. 8-K filings
Get the next HRMY 8-K as it lands
Follow HRMY for push alerts, or ask the research agent what this filing means.